These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9516088)

  • 21. Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.
    Lewalle P; Martiat P
    Leuk Lymphoma; 1993; 11 Suppl 1():139-43. PubMed ID: 8251887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligonucleotide therapeutics for hematologic disorders.
    Agarwal N; Gewirtz AM
    Biochim Biophys Acta; 1999 Dec; 1489(1):85-96. PubMed ID: 10806999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic applications of antisense DNA in the treatment of human leukemia.
    Gewirtz AM
    Ann N Y Acad Sci; 1992 Oct; 660():178-87. PubMed ID: 1285070
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
    Pigneux A; Mahon FX; Jazwiec B; Pigeonnier V; Ripoche J; Reiffers J
    Leuk Lymphoma; 2000 Feb; 36(5-6):569-78. PubMed ID: 10784402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
    Rowley PT; Kosciolek BA; Kool ET
    Mol Med; 1999 Oct; 5(10):693-700. PubMed ID: 10602778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
    Kronenwett R; Haas R
    Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714
    [No Abstract]   [Full Text] [Related]  

  • 30. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
    Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG
    Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
    Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
    Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
    J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
    Chasty R; Whetton A; Lucas G
    Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospects for antisense therapy of human leukemias].
    Maekawa T
    Hum Cell; 1996 Mar; 9(1):17-24. PubMed ID: 9183625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.